ReviewTrends in molecular medicine2007
The HER family and cancer: emerging molecular mechanisms and therapeutic targets.
Review in Trends in molecular medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 143 citations in OpenAlex.
- Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.British journal of cancer · 2026Trial
- Exploring the Role ofHealth science reports · 2026Article
- Loss of hormone receptor expression in breast tissue following pre-surgical therapy with an SERD.Histopathology · 2026Article
- Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.NPJ precision oncology · 2026Article
- HER3 and FOLR1 Expression as Actionable Targets in High-Grade Serous Ovarian Carcinoma: Prognostic and Therapeutic Implications.Medicina (Kaunas, Lithuania) · 2026Observational
- Decoding breast cancer: insights into molecular pathways & therapeutic approaches.Discover oncology · 2025Review
- Single cell sequencing and computational findings reveal anti-estrogen receptor-positive breast cancer roles of formononetin.Scientific reports · 2025Article
- Editorial to "A Plant-Powered Remedy: Hyperoside's Potential Against Trastuzumab-Induced Cardiotoxicity" by Bullock et al.Cardiovascular drugs and therapy · 2025Article
- Article
- Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.Cancer discovery · 2025Article
- Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review.Journal of clinical medicine · 2024Review
- Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells.World journal of oncology · 2024Article
- Human epidermal growth receptor polymorphisms (Health science reports · 2024Article
- HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Article
- Review
- Benchmarking integration of single-cell differential expression.Nature communications · 2023Article
- HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.Journal of cancer research and clinical oncology · 2023Article
- EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.Scientific reports · 2022Article
- Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer.Cancers · 2022Article
- MicroRNAs as a clue to overcome breast cancer treatment resistance.Cancer metastasis reviews · 2022Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The human epidermal growth factor receptor (HER) family of transmembrane tyrosine kinases regulates diverse cellular functions in response to extracellular ligands. The deregulation of HER signaling through gene amplification or mutation is seen in many human tumors and an abundance of experimental evidence supports the etiological role of these events in cancer pathogenesis. In addition, the fact that they are feasible targets for both antibody and small-molecule therapeutics has made them highly pursued targets for the development of rationally designed anticancer drugs. Several HER-targeting agents have entered clinical practice and this has led to novel discoveries regarding the mechanisms of resistance, which has defined a new generation of challenges for targeted cancer therapies. Here, we review recent advances in our understanding of HER signaling and targeting in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.